Atiprimod (SKF 106615, Azaspirane) is a potent, orally bioavailable JAK2 inhibitor, inhibits phosphorylation of JAK2 and the downstream STAT3 and STAT5 pathways.
Atiprimod (SKF 106615, Azaspirane) is a potent, orally bioavailable JAK2 inhibitor, inhibits phosphorylation of JAK2 and the downstream STAT3 and STAT5 pathways.
Atiprimod efficaciously inhibits the proliferation of FDCP-EpoR JAK2 (V617F) (IC50=0.42 uM) and SET-2 cells (IC50= 0.53 uM).
Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells (MM.1S, U266, and RPMI8226 MM cell lines IC50=0.5-1.25 uM), significantly inhibits production of IL-6 and inflammation in rat arthritis and autoimmune animal models.
